vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $188.3M, roughly 1.5× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -45.7%, a 93.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -21.9%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -15.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GH vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $188.3M |
| Net Profit | $-128.5M | $90.3M |
| Gross Margin | 64.6% | 79.5% |
| Operating Margin | -43.0% | 32.3% |
| Net Margin | -45.7% | 47.9% |
| Revenue YoY | 39.4% | -21.9% |
| Net Profit YoY | -15.8% | 1710.8% |
| EPS (diluted) | $-1.01 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $188.3M | ||
| Q3 25 | $265.2M | $215.3M | ||
| Q2 25 | $232.1M | $188.2M | ||
| Q1 25 | $203.5M | $197.2M | ||
| Q4 24 | $201.8M | $241.0M | ||
| Q3 24 | $191.5M | $225.5M | ||
| Q2 24 | $177.2M | $256.0M | ||
| Q1 24 | $168.5M | $263.4M |
| Q4 25 | $-128.5M | $90.3M | ||
| Q3 25 | $-92.7M | $91.1M | ||
| Q2 25 | $-99.9M | $139.5M | ||
| Q1 25 | $-95.2M | $-10.0M | ||
| Q4 24 | $-111.0M | $-5.6M | ||
| Q3 24 | $-107.8M | $-284.4M | ||
| Q2 24 | $-102.6M | $-433.6M | ||
| Q1 24 | $-115.0M | $-49.2M |
| Q4 25 | 64.6% | 79.5% | ||
| Q3 25 | 64.7% | 83.7% | ||
| Q2 25 | 65.0% | 81.3% | ||
| Q1 25 | 63.3% | 81.4% | ||
| Q4 24 | 61.6% | 79.8% | ||
| Q3 24 | 61.1% | 82.1% | ||
| Q2 24 | 59.1% | 84.5% | ||
| Q1 24 | 61.2% | 85.3% |
| Q4 25 | -43.0% | 32.3% | ||
| Q3 25 | -37.3% | 30.4% | ||
| Q2 25 | -45.9% | 5.7% | ||
| Q1 25 | -54.6% | -31.2% | ||
| Q4 24 | -62.4% | -69.2% | ||
| Q3 24 | -61.3% | -36.4% | ||
| Q2 24 | -56.8% | -90.8% | ||
| Q1 24 | -59.2% | -6.1% |
| Q4 25 | -45.7% | 47.9% | ||
| Q3 25 | -35.0% | 42.3% | ||
| Q2 25 | -43.0% | 74.1% | ||
| Q1 25 | -46.8% | -5.1% | ||
| Q4 24 | -55.0% | -2.3% | ||
| Q3 24 | -56.3% | -126.1% | ||
| Q2 24 | -57.9% | -169.4% | ||
| Q1 24 | -68.2% | -18.7% |
| Q4 25 | $-1.01 | $2.78 | ||
| Q3 25 | $-0.74 | $2.91 | ||
| Q2 25 | $-0.80 | $4.50 | ||
| Q1 25 | $-0.77 | $-0.39 | ||
| Q4 24 | $-0.90 | $-0.01 | ||
| Q3 24 | $-0.88 | $-9.39 | ||
| Q2 24 | $-0.84 | $-14.35 | ||
| Q1 24 | $-0.94 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $226.6M |
| Total DebtLower is stronger | $1.5B | $1.4B |
| Stockholders' EquityBook value | $-99.3M | $-171.5M |
| Total Assets | $2.0B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $226.6M | ||
| Q3 25 | $580.0M | $184.2M | ||
| Q2 25 | $629.1M | $267.4M | ||
| Q1 25 | $698.6M | $138.3M | ||
| Q4 24 | $525.5M | $146.9M | ||
| Q3 24 | $585.0M | $159.2M | ||
| Q2 24 | $933.7M | $236.9M | ||
| Q1 24 | $1.0B | $190.7M |
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $-171.5M | ||
| Q3 25 | $-354.5M | $-260.5M | ||
| Q2 25 | $-305.5M | $-351.7M | ||
| Q1 25 | $-250.8M | $-496.8M | ||
| Q4 24 | $-139.6M | $-488.2M | ||
| Q3 24 | $-60.1M | $-497.6M | ||
| Q2 24 | $-1.6M | $-218.3M | ||
| Q1 24 | $68.3M | $228.4M |
| Q4 25 | $2.0B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.5B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.7B | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $26.2M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $26.2M | ||
| Q3 25 | $-35.4M | $-60.6M | ||
| Q2 25 | $-60.3M | $-25.6M | ||
| Q1 25 | $-62.7M | $184.0K | ||
| Q4 24 | $-64.5M | $-2.7M | ||
| Q3 24 | $-51.1M | $19.5M | ||
| Q2 24 | $-94.0M | $111.5M | ||
| Q1 24 | $-30.3M | $135.4M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
